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Abstract The rationale of current exploration was to
formulate positively charged amikacin-loaded polymeric
nanoparticles providing a controlled release attribute.
Amikacin sulphate-loaded nanoparticles were prepared by
w/o/w emulsification solvent evaporation approach suc-
ceeded by high-pressure homogenization. Two bioadhesive
positively charged polymers, Eudragit RS 100 and Eu-
dragit RL 100, were used in the blend, with variable ratios
of drug and polymer. The formulations were assessed in
terms of particle size and zeta potential. Thermal gravi-
metric analysis was brought out on the samples of drug,
polymer and drug polymer complex. Drug loading and
release attributes of the nanoparticles were scrutinized and
antimicrobial activity in contrast to Staphylococcus aureus
was appraised. Ocular irritation test, in vivo ocular reten-
tion study, in vivo release profile (permeation study) and
in vivo antibacterial activity of polymeric nanosuspensions
were executed. No rupture consequence but a lengthened
drug release was contemplated from all formulations.
Amikacin sulphate release from the polymeric
nanoparticles reflected a better fit with Korsmeyer–Peppas
model. In the course of the antibacterial activity of nano-
particles against S. aureus, formulation AE1 displays the
most prominent inhibitory effect as compared with mar-
keted formulation of amikacin sulphate.
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Introduction
Anatomically and physiologically eye is an intricate and
inimitable organ cagey by a number of defensive machin-
eries. The anatomy, physiology and biochemistry of the
eye transcribe this organ immensely impervious to unfa-
miliar substances (Satish and Paramita 2006). Miscella-
neous arrangements protecting the eye from noxious
entities and agents such as lacrimation, reflex blinking,
drainage, prompt tear turnover and precorneal loss ends in
very dissatisfying absorption of topically executed oph-
thalmic drugs, as a consequence, recurrent installation of
considerably concentrated solutions or suspension of drug
is demanded (Emami 2006). A grave challenge to the
formulator is to conquer the defending barriers of the eye
without generating everlasting tissue damage, evolvement
of newer, additionally responsive diagnostic systems and
innovative therapeutic agents continue to provide ocular
delivery systems with high therapeutic efficacy (Mitra
2009).
In the field of formulation development of ophthalmic
dosage form, foremost constrained is insufficient corneal
residence time of the drug molecule, consequenting in poor
pharmacotherapeutics. To fix this trouble, a number of
efforts were performed in the former times by formulating
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miscellaneous ophthalmic drug delivery systems in dispa-
rate formats such as hydrogels (Derwent and Mieler 2008),
microparticles (Joshi 1994), nanoparticles (Nagarwal et al.
2009), liposomes (Nagarsenker et al. 1999), collagen
shields (Yoel and Guy 2008), ocular inserts/discs
(Bloomfield et al. 1978), dendrimers (Vandamme and
Brobeck 2005) and transcorneal iontophoresis (Monti et al.
2003) etc. All of the attempts made in the history were
executed with a target to defeat the swift elimination of
active agent from the precorneal cavity of the eye and to
boost the corneal residence time of the drug molecules.
Over the last decade, diverse new drug delivery systems,
such as liposomes, microparticles as well as nanoparticles,
designed for the ophthalmic administration of active drug
moieties, have been developed, and such formulations
claim prolonged action with comfortable application of
formulation in eye drop form. Nanoparticles have been
established to be the most promising of all the formulations
developed over the past a couple of years of marked
investigations in ocular therapeutics, owing to their sus-
tained release and prolonged therapeutic involvement.
Polymeric nanoparticles are also capable of target ailments
in the posterior segment of the eye (Antoine et al. 2005).
Following the administration of the drug, nanoparticulate
carrier can retain at the application site (cul-de-sac) and
prolonged action of drug may result from drug diffusion
from the particles, erosion or degradation of particles, or by
the combination of both mechanisms (Soppimath et al.
2001).
Polymeric nanosuspensions were prepared from Eudra-
git RL 100 and Eudragit RS 100 observing that they are
approved by USFDA as an excipient for controlled drug
delivery. Due to their competence to form nanodispersion
with smaller particle size, positive surface charge, excellent
stability, lack of any irritant effect on the cornea, iris and
conjunctiva, Eudragit nanoparticles come forth to be a
suitable inert carrier for ophthalmic drug delivery (Hazn-
edar and Dortunc 2004). They are inert polymer resins,
insoluble at physiologic pH but have swelling properties.
The delivery system was intended to enhance ocular
availability without blurring vision and diminishing the
frequency of dosing in conjunctivitis leading to patience
compliance. Positive surface charge of nanoparticles can
allow longer residence time for the drug on the eye surface
by increasing the interaction of nanoparticles with the
glycoprotein of the cornea and conjunctiva. It can form a
precorneal depot resulting in the prolonged release of the
bound drug from nanoparticles (Wagner and Mc-Ginity
2002; Knop 1996).
Amikacin sulphate, a potent broad spectrum antibiotic is
picked as the model drug for the management of diverse
acute infections of the eye, remarkably in the anterior
segment, considering that it is a prime drug for the remedy
of numerous grave gram-negative bacterial infections of
eye and traditionally is the aminoglycoside of foremost
choice on account of its low cost and reliable activity
against all but the majority of resistant gram-negative
bacteria. They are bacteriostatic in nature and interfere
with protein synthesis in bacterial cells by binding to 30S
ribosomal subunit, leading to bacterial cell death (Alonso
et al. 1989).
Staphylococcus aureus, most common ocular pathogen
causing bacterial infection of the human cornea, was
selected as test microorganism during the determination of
antimicrobial activity of the prepared formulations (Arm-
strong 2000; Bourcier et al. 2003).
Present study was executed with a goal to evaluate the
nanoparticle formation process, physicochemical proper-
ties and in vitro and in vivo activity of amikacin sulphate-
loaded polymeric nanoparticles prepared from Eudragit
RS 100 and RL 100 in diverse ratios. Moreover, the
objective of the investigation was to formulate positively
charged nanoparticles of amikacin sulphate, which could
interact with the anionic mucin present in the mucus layer
of the tear film.
Experimental
Materials and methods
Materials, microorganism and animals
The Eudragit RS100 and RL100 polymers were pur-
chased from Evonik Degussa India Private Limited
(Mumbai, India) and Polyvinyl alcohol (PVA; MW 95,
000) was supplied by Sigma-Aldrich (India). Amikacin
sulphate was donated as a gift sample by Cadila Pharma-
ceuticals Limited (Dholka, Gujarat, India). All supple-
mentary chemicals were of reagent grade. Eudragit RS
100 and RL 100, PVA and other chemicals were used as
provided by the manufacturers without further purification.
Microorganism S. aureus (ATCC 6538) was procured from
Institute of Microbial Technology (Chandigarh, India).
Male healthy albino rabbits having weight order of
1.5–2.0 kg were put to use for the amikacin ocular
pharmacokinetics.
Formulation of Eudragit RS 100/RL 100 polymeric
nanoparticles
Optimization of Polymer proportion and Sonication period
Polymer ratios of Eudragit RL 100 and RS 100 were
optimized under identical experimental environment on the
ground of assessment of particle size and zeta potential of
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prepared nanoparticles. In the same way, the consequences
of sonication time on the entrapment efficiency and size of
nanoparticles were assessed, since the period and magni-
tude of ultrasonication influence the size of nanoparticles,
which is the most significant attribute of nanoparticles as a
drug carrier.
Preparation of amikacin sulphate-loaded Eudragit RS
100/RL 100 nanoparticles
Nanoparticles were prepared by w/o/w emulsification sol-
vent evaporation approach immediately succeeded by high-
pressure homogenization (Dillen et al. 2004). Keeping drug
constant at 250 mg and varying polymer concentration,
distinct ratios of drug and polymer were utilized for the
preparation of nanoparticles. Individually, sample was
manufactured in triplicate.
In 20 ml of methylene chloride containing the polymer
mixture of Eudragit RL 100 and RS 100, 5 ml of an
aqueous amikacin sulphate solution (5 % w/v) was
emulsified with the assistance of the ultrasound probe for
60 s at 40 W. Prepared w/o emulsion was immediately
poured in 25 ml of a PVA stabilizer solution (1 % w/v in
water), and sonicated for 60 s at 40 W to obtain a mul-
tiple emulsion. Acquired multiple emulsion was subse-
quently homogenized with the aid of a homogenizer
(Microfluidics, Newton, USA) at a pressure of 60 bars
through three cycles. Resultant emulsion was diluted in
100-ml PVA solution (0.2 % w/v in water) to minimize
coalescence. The mixture was persistently agitated on a
magnetic stirrer for 6 h and 500 rpm at room temperature
to permit solvent evaporation and particle formation. To
acquire isotonicity following reconstitution and for ease
of redispersion of the solid nanoparticles by physical
agitation, the cryoprotectant mannitol was blended in a
5 % (w/v) concentration succeeding freeze drying. The
resulting nanosuspension was later on cooled down to
-20 C and freeze dried.
Evaluation of the nanoparticles
Morphological characterization
Eudragit nanoparticles were identified for the morphol-
ogy with the facility of scanning electron microscope
(SEM) (XL-30 Philips, Eindhoven, The Netherlands). The
nanosuspensions were deposited on a glass disc applied
on a metallic stub and evaporated under a vacuum
overnight. The samples were metallized under an argon
atmosphere with a 10-nm gold palladium thickness before
the SEM analysis (EMITECH-K550 Sputter Coater,
Houston, TX).
Nanoparticle size and zeta potential analysis
Photon correlation spectroscopy (Zetasizer, Beckman
Coulter Inc., Delsa Nano 4C) was used for the determi-
nation of size distribution (polydispersity index) and zeta
potential. For the size distribution, samples were appro-
priately diluted with filtered water (0.2-lm filter; Minisart,
Germany) and analysis was carried out at a temperature of
25 C and scattering angle of 90, while zeta potential was
estimated utilizing a disposable zeta cuvette. All assess-
ments were executed in triplicate (n = 3), and the standard
deviation (SD) was noted.
Determination of encapsulation efficiency of nanoparticles
For the determination of encapsulation efficiency, drug-
loaded nanoparticles were separated from the aqueous
medium (supernatant) containing unloaded amikacin sul-
phate, with the help of the ultracentrifugation process for
30 min at 20,000 rpm and 4 C temperature (REMI high
speed, cooling centrifuge, REMI Corporation, India). The
remaining quantity of unloaded amikacin sulphate in the
supernatant was estimated spectrophotometrically at
568 nm (Yang et al. 2005; Motwani et al. 2008). The
amount of encapsulated amikacin sulphate into the nano-
particles was calculated using (Eq. 1).
Encapsulation efficiency ð%Þ
¼ Total Amikacin  Free Amikacin
Total Amikacin
 100 ð1Þ
Fourier transform infrared spectroscopy (FTIR) analysis
FTIR transmission spectra of freeze-dried amikacin sul-
phate-loaded nanoparticles were acquired utilizing a FTIR
spectrophotometer (Perkin-Elmer, USA, model BX2).
Individually KBr disc was scanned at 4 mm/s at a resolu-
tion of 2 cm over a wavenumber region of
400–4,000 cm-1. The characteristic peaks were noted for
different samples.
Thermal analysis
To inquiry the thermal aspects of drug, polymers and
complex of drug and polymer, thermal gravimetric analysis
(TGA) approach was used. With the assistance of an auto-
matic thermal analyzer system (Diamond TG/DTA 8.0,
Perkin-Elmer, USA) TGA thermograms were achieved.
Samples of drug, polymer and drug polymer complex were
crimped in standard aluminium pans and heated from 40 to
500 C (heating rate 10 C/min) under constant purging of
dry nitrogen (20 ml/min). For the reference, an empty pan
sealed in the same way as the sample, was used.
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In vitro studies
In vitro drug release tests
For the assessment of drug release pattern from amikacin-
loaded polymeric nanoparticles a diffusion cell was used,
whereby a dialysis membrane with a molecular weight
cutoff of 12,000–14,000 Da (Medicell International,
London, United Kingdom) divided the acceptor from the
donor compartment, and the entire investigation was
executed in triplicate. 5 ml of amikacin sulphate nano-
suspension holding drug equivalent to 50 mg was depos-
ited in donor compartment, and the acceptor compartment
was stocked with 50 ml of simulated tear fluid. Simulated
tear fluid agitated magnetically at 200 rpm. Periodically,
12 (0–12 h) aliquots (1 ml) were withdrawn from the
acceptor compartment and restored by the same volume of
fresh STF solution to retain a constant volume. Sink
conditions were kept up during the whole study. For the
quantitative analysis, UV–Vis spectrophotometry was
utilized (Shimadzu UV-1800) at 568.0 nm. All assess-
ments were completed in triplicate and the SD was
calculated.
For the statistical analysis, four principally practised
mathematical models were picked out for the estimation of
release of amikacin from amikacin-loaded nanoparticles,
i.e. zero-order model (Eq. 2), first-order model (Eq. 3),
HiguChi square root model (Eq. 4) and Korsmeyer–Peppas
model (Eq. 5).
%Qt=%Q1 = K  t ð2Þ
%Qt=%Q1 = 1  e
Kt ð3Þ
%Qt=%Q1 ¼ K  t
1=2 ð4Þ
%Qt=%Q1 ¼ K  t
n ð5Þ
where %Qt is the percentage drug release at time t, %Q? is
the total percentage drug released, %Qt/%Q? is the frac-
tion of drug release at time t; K is the release rate constant
and n is the diffusional release exponent that could be used
to characterize the different release mechanisms [n B 0.45
(Fickian diffusion), 0.45 \ n \ 1 (anomalous transport)
and n = 1 (case II transports; i.e. zero-order release)]
(Ritger and Peppas 1987; Pandey et al. 2011).
Data obtained during in vitro drug release assessment
were treated complementing zero-order (cumulative
amount of drug release vs time), first-order (log cumulative
percentage of drug remaining vs time), Higuchi (cumula-
tive percentage of release vs square root of time) and
Korsmeyer–Peppas (log cumulative percentage of drug
released vs log time) equation models. Excel 2007
(Microsoft Corporation, Redmond, WA, USA) was used
to evaluate the outcomes of in vitro drug release figures to
acquire the best fit kinetic model for in vitro release.
In vitro antimicrobial activity
Assessment of antimicrobial action of formulated amika-
cin-loaded nanoparticles was performed taking a marketed
eye drop of amikacin solution as a standard (Amipar eye
drop, Bio Medica International, Ludhiana, India), and S.
aureus (ATCC 6538) was used as a test organism. Nutrient
agar was prepared and sterilized by autoclaving (at 121 C/
15 psi pressure for 20 min). 20 ml of medium previously
inoculated with the test microorganism (0.2 ml of stock)
was transferred to the Petri plate and permitted to solidify.
Following solidification, with the assistance of a sterile
bored of 4-mm diameter cups were constructed on the
solidified agar layer. Now a volume of the formulated
amikacin nanoparticulate suspension and marketed ami-
kacin eye drop was poured into the cups after keeping in
record that both formulations contain an equivalent amount
of drug. Before incubation, Petri plates were left at room
temperature for 4 h, afterwards plates were incubated at
37 C for 24 h. The zones of inhibition were obtained and
diameter of the zone of inhibition was calculated with the
assistance of an antibiotic zone finder. Figures were
recorded in triplicate.
In vivo studies
Male New Zealand albino rabbits were used for in vivo
studies. All the rabbits used have the weight in the range of
2.0–2.5 kg, and they were free from any character of ocular
inflammation and or gross deformities. Before performing
an experiment, all the rabbits were adapted in our institu-
tion animal facility for 1 week. The rabbits were housed as
per standard conditions, i.e. at 22 ± 2 C temperature,
50–70 % relative humidity and with 12 h light/dark cycle.
The rabbits were separately housed with plenty of food,
and water provided ad libitum. The diverse in vivo studies
were carried out with the approval and in accordance with
the Institutional Animal Ethics Committee (IAEC) consti-
tuted as per directions of the Committee for the Purpose of
Control and Supervision of Experiments on Animals
(CPCSEA), under the Ministry of Animal Welfare Divi-
sion, Government of India, New Delhi (Approval No. BU/
Pharm/11/32).
Ocular irritation test
Ocular irritation test for the optimized amikacin-loaded
nanosuspension was evaluated by rabbit winking test
(Pignatello et al. 2002). Total nine rabbits were divided
into three groups. Group I as the control group received
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simulated tear fluid of pH 7.4, group II was treated with
marketed eye drop of amikacin sulphate solution, and
group III was treated with optimized formulation (AEI) of
nanosuspension. The 30-ll formulations were instilled into
the left eye of the rabbits, and the rabbits were forced to
wink once to spread the formulations uniformly on the
corneas. Then the frequency of rabbit winking in 5 min
after instillation was recorded.
In vivo ocular retention study
For the ocular retention study, scanning electron micro-
scope (SEM) (FEI Quanta 200, USA) approach was uti-
lized. For this purpose, SEM micrograph of corneal surface
and SEM micrograph of corneal surface later 6 h of
treatment with nanosuspension were captured.
Permeation study/in vivo release profile
Three New Zealand albino rabbits were utilized for per-
meation study, and all the rabbits received the 30 ll of
optimized nanosuspension in one eye (right) and two drops
of the commercial amikacin eye drop (Amipar, Bio Medica
International, Ludhiana, India) as control in the left eye and
eye was forced to blink three times. Employing a 28-gauge
needle attached to 1-ml tuberculin syringe, samples of
aqueous humour (50 ll) were collected from the anterior
chamber of each eye at the time intervals of 0.5, 1, 2, 4, 8
and 12 h instantly after instillation of local anaesthetic
(4 % xylocaine solution). Now aqueous humour samples
were centrifuged (15,000 rpm for 15 min) and 20 ll of the
supernatant was examined for the drug employing UV
spectrophotometer (SHIMADZU UV-1800), afterwards the
rabbits were killed.
Various pharmacokinetic parameters such as maximum
drug concentration (Cmax) and the time of maximum drug
concentration (tmax) were evaluated from concentration vs.
time profiles. Employing the trapezoidal method, the area
under the concentration–time curve (AUC0-12) was
estimated.
To evaluate the statistical difference between the two
treatments for the extent of drug absorption in both ocular
tissues (AUC0-12) Paired t test (at p \ 0.01) was used.
In vivo antibacterial activity
In vivo antibacterial investigation was accomplished using
nutrient agar as growth medium and bacterial culture of S.
aureus (ATCC 6538). Bacterial culture was sourced from
IMTECH (Institute of Microbial Technology), Chandigarh.
The bacterial culture maintained on nutrient agar on Petri
dishes was sub-cultured in liquid nutrient medium, kept on
the rotary flask shaker at 37 C and allowed to grow
overnight. The inoculum so prepared was used further to
produce infection in rabbits. Three groups of rabbit (six
albino rabbit in each group) weighing 2.0–2.5 kg were
selected and the bacterial inoculum of S. aureus was
inoculated into the right eye in groups I, II and III with the
help of a transfer loop. Thus, the infection was produced
after 2 days. For the determination of antibacterial activity,
three different preparations of amikacin sulphate were used
on following groups, group, I (Control), group II (treated
with amikacin sulphate-loaded nanoparticles), and group
III (treated with amikacin sulphate) (Amipar, Bio Medica
International, Ludhiana, India).
Physical parameters were recorded up to 6 days after
treatment in all groups. After treatment of the rabbits with
different preparations (i.e. nanosuspension was instilled
twice a day, while the commercial amikacin solution was
instilled four times a day during the study period), the
rabbit’s eyes were observed for discharge, redness and
swelling up to 6 days.
Storage stability studies
To review the physical stability of optimized nanosuspen-
sion formulation (AE1) and dried nanoparticles (AE1*),
aliquots of the nanosuspension formulation were freeze
dried. 5 % w/v mannitol was added to 100-ml aliquots of
samples as a cryoprotectant; all the aliquots were frozen in
liquid nitrogen and then lyophilized (Heto Drywinner,
Thermo Scientific, USA) for a period of 48 h, at -60 C,
and 0.05 mmHg pressure.
Physical stability protocol for the nanosuspension for-
mulation and lyophilized nanoparticles was designed
according to the standards of ICH. For this study, exact
volumes of each nanosuspensions were stored in closed
glass bottles for 6 months under different temperature
conditions, i.e.at 5 ± 2 C (in refrigerator) and at 25 C/
60 % relative humidity (RH) in dark conditions. After
6 months, aliquots of 2 ml were withdrawn from all sam-
ples to measure particle size and drug loading.
Results and discussion
Formulation of Eudragit RS100/RL100 polymeric
nanoparticles
Optimization of polymer proportion and sonication period
For the optimization of the polymer ratio, five batches
specifically F1, F2, F3, F4 and F5 having Eudragit RS
100 and Eudragit RL 100 ratios of 10:90, 30:70, 50:50.
70:30 and 90:10 were formulated. Following determination
of particle size and zeta potential of all batches, it was
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perceived that formulation F3 having Eudragit RS 100
and Eudragit RL 100 ratio of 1:1 was found to be most
optimal since the particle size range of F3 formulation
existed in mid of 180–184 nm and zeta potentials in the
order of 35.4–37.2 mV. Rest formulations such as F4 and
F5 were ranked in particle size above 200 nm, since par-
ticle size preceding 200 nm is not admissible in ocular
dosage form hence those formulations were rejected. On
the other hand, formulations F1 and F2 hold zeta potential
exceeding 40 mV which was also not suitable for stability
of formulation, as a consequence those formulations were
also not considered (Table 1).
In the same way to establish the influence of sonication
time on the size of nanoparticles, different formulations
were sonicated for the period of 30, 60 and 90 s at the time
of preparation. On monitoring the particle size of the all
prepared formulations, it was perceived that on expanding
the time span of sonication from 30 to 60 s the dimension
of nanoparticles downturns, however, on the further
extension in sonication period up to 90 s the dimensions of
nanoparticles once more steps up with a little increase in
the zeta potential value (Table 1).
Probably, it takes place due to high energy generation
caused by the increase in sonication time, consequenting in
aggregation of nanoparticles and leads to increase in
nanoparticles size. Sometimes in the condition of high
energy, mechanical energy is transformed into kinetic
energy, which affects the zeta potential of nanoparticles.
Supplementally high energy influences the charge of the
shear plane, resulting in an increase of the zeta potential.
Sometime longer sonication period may bring out chemical
changes in the solvent molecule’s environment, which
alters the size and zeta potential of nanoparticles.
The formulation code F3 with sonication time 60 s was
found having optimum polymer ratio suitable for devel-
oping ocular drug delivery system as the mean particle size
and zeta potential are well within range, i.e. particle size
below 200 nm and zeta potential between 20 and 40 mV.
Preparation of amikacin sulphate-loaded Eudragit RS
100/RL 100 nanoparticles
For the optimization of drug and polymer ratio for the
formulation of amikacin sulphate-loaded nanoparticles,
various ratios of drug and polymer were selected, specifi-
cally drug and polymer ratio of 1:1, 1:5, 1:15 and 1:20
(keeping Eudragit RS 100/Eudragit RL 100 polymer
composition fixed at 50/50). Following formulation of
Amikacin sulphate-loaded nanoparticles having all the
selected proportion of drug and polymer, particle size,
encapsulation efficiency, in vitro release profile and
mechanism were determined for all formulations (Table 2).
Later on studying entire statistics acquired from diverse
formulations, it was figured that alteration in drug and
polymer proportion considerably influences the particle
size, encapsulation efficiency, in vitro release profile and
mechanism. Outcomes project that higher polymer ratio
culminated in higher particle sizes, and increase in the drug
and polymer ratio results in diminishing of encapsulation
efficiencies for amikacin sulphate. Outcomes obtained in
the present investigation exhibits dissimilarity in result to
that publicized by Dillen et al. (2006) and Pignatello et al.
Table 1 Optimization of polymer ratio and sonication period for amikacin sulphate-loaded polymeric nanoparticles
Formulation
batch code





(mean ± SD) (nm)
Zeta potential (mean ± SD)
(mV), n = 3
F1 10:90 30 128 ± 22.6 46.3 ± 0.4
60 122 ± 26.2 43.2 ± 0.3
90 126 ± 21.7 44.1 ± 0.3
F2 30:70 30 159 ± 14.3 42.1 ± 0.3
60 153 ± 16.1 41.2 ± 0.4
90 154 ± 20.1 40.6 ± 0.2
F3 50:50 30 184 ± 16.3 37.2 ± 0.2
60 180 ± 19.1 35.4 ± 0.3
90 181 ± 18.2 36.1 ± 0.2
F4 70:30 30 208 ± 24.1 33.2 ± 0.4
60 202 ± 19.3 32.1 ± 0.3
90 204 ± 21.7 32.8 ± 0.3
F5 90:10 30 242 ± 24.4 31.1 ± 0.4
60 236 ± 26.4 29.8 ± 0.2
90 238 ± 23.7 30.4 ± 0.2
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(2006), in which it was stated that the drug and polymer
ratio did not influence the drug loading encapsulation
efficiencies. Outcomes also project that increase in the drug
and polymer ratio considerably hampered the release of
Amikacin sulphate.
On behalf of aboveground, formulation having batch
code AE1 of the amikacin sulphate nanoparticle suspen-
sion, that was prepared utilizing 1:1 drug to the polymer
ratio exhibited the lowest mean particle size, highest drug
content and release efficiency. On the ground of the
abovementioned result, the nanoparticles prepared at a
drug:polymer ratio of 1:1 and Eudragit RS 100/Eudragit
RL 100 ratio of 50:50 (AE1) were picked out to be eval-
uated in vivo.
Evaluation of the nanoparticles
Morphological characterization: nanoparticle size
and zeta potential analysis
Amikacin-loaded Eudragit nanoparticles were character-
ized for the morphology with the help of scanning electron
microscope (SEM) (XL-30 Philips, Eindhoven, The
Netherlands). SEM photomicrograph (Fig. 1) shows the
presence of definite and regular nanoparticles. No sign of
large aggregation was detected during a microscopic
examination.
The mean particle size of formulation ranges from 149
to 248 nm; on altering polymer ratios and keeping the drug
constant, the particle size, encapsulation efficiency, in vitro
release profile and mechanism influenced considerably.
With the rise in the polymer ratios, the particle size raised
proportionally. The results are shown in Table 1.
Results of zeta potential analysis project that every
formulated batch displays positive zeta potential estimate.
Since positive zeta potential is an important aspect which
eases efficient adherence to the anionic mucin layer of the
cornea, which consequent in lengthening of the drug
release period and enhancement of the drug approachabil-
ity to the ocular tissues (Pignatello et al. 2002). The mean
zeta potential of nanoparticles of optimized formulation
AE1 was found to be 25.69 mV, which is pondered
appropriate for stability aspects.
Solid-state characterization of drug polymeric system:
Fourier transform infrared spectroscopy (FTIR)
To estimate the fundamental interactions of drug to the
polymer drug amikacin sulphate, polymers Eudragit RL
100/Eudragit RS 100 and drug-loaded polymeric nano-
particles were examined employing FTIR spectrophotom-
eter for typical absorption bands.
The N–H bending vibration of primary aromatic amines
exhibits peaks at the 1,650–1,540 cm-1 range of the
spectra. The peak at 1,637 cm-1 in both spectra of drug
amikacin sulphate and amikacin sulphate-loaded poly-
meric nanoparticles formulation depicts that –NH2 group
of amikacin sulphate is untreated, which represents the
absence of interaction between drug and polymer. Par-
allelly, peaks noticed in the mid of 3,700–3,584 cm-1 in
FTIR spectra of drug amikacin sulphate and amikacin
sulphate-loaded polymeric nanoparticles, peak at
3,391 cm-1 represents untreated ‘‘free’’ hydroxyl groups










(mean ± SD) (mV),
(n = 3)
Polydispersity
index (nm ± SD)
Encapsulation efficiency
(%) ± SD, (n = 3)
Release efficiency
after 12 h (n = 3)
AE1 1:1 149 ± 16.2 25.69 ± 1.4 0.232 ± 0.01 80.94 ± 2.3 90.82 ± 3.9
AE2 1:5 187 ± 19.6 26.83 ± 2.2 0.298 ± 0.03 79.23 ± 2.9 71.82 ± 3.2
AE3 1:10 218 ± 23.6 26.62 ± 3.1 0.358 ± 0.03 78.12 ± 2.5 49.22 ± 2.6
AE4 1:15 237 ± 24.4 26.13 ± 1.9 0.406 ± 0.02 76.34 ± 2.3 43.38 ± 2.6
AE5 1:20 248 ± 25.7 26.91 ± 3.3 0.468 ± 0.04 72.16 ± 2.9 39.43 ± 2.3
Fig. 1 SEM photomicrograph of amikacin sulphate-loaded
nanoparticles
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of amikacin sulphate. FTIR spectroscopy spectacle that
there are no considerable interactions among the drug
amikacin sulphate and the elected polymers Eudragit RS
100 and Eudragit RL 100 employed in the formulation of
amikacin sulphate-loaded polymeric nanoparticles
(Fig. 2a, b).
Thermogravimetric analysis (TGA)
The results from the TGA showed two significant weight
losses for the amikacin sulphate below 105 C and at
190–270 C, while the TGA curve of Eudragit polymers
showed single significant weight loss between 325 and
400 C. In contrast, the amikacin sulphate polymeric
nanoparticles better thermal stability in comparison to
amikacin sulphate alone. Less than 7 % weight loss is
observed below 200 C. Furthermore, the gradual weight
loss occurs up to 295 C (Fig. 3).
Fig. 2 a FTIR Spectra of
amikacin sulphate. b FTIR of
amikacin sulphate-loaded
nanoparticle
Fig. 3 Thermogravimetric analysis (TGA) of amikacin sulphate,
Eudragit RS 100/RL 100 and amikacin sulphate-loaded Eudragit
nanoparticles
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In vitro studies
In vitro drug release tests
The in vitro release study of the developed formulations
AEI to AE5 was carried out for 12 h. In these formulations,
the percentage drug release was varied from 39.43 to
90.82 %. Release of the drug decreases, with the increase
in amount of the polymers Eudragit RL/RS 100. This may
be due to the decrease in the influx of dissolution media
(Fig. 4).
In vitro drug release studies revealed constant drug
release and no burst effect was observed indicating that the
drug was homogeneously dispersed in the Eudragit
polymeric matrix and there were no significant amount of
drug adsorbed onto the surface of nanoparticles. Within all
the formulations, the maximum percentage of in vitro drug
release was found to be 90.82 % for the formulation AEI,
having drug:polymer ratio 1:1. The correlation coefficient
(r2) was found to be 0.98 for AEI.
Further in order to study the mechanism of amikacin
sulphate release from the polymeric nanoparticles, data
obtained from the in vitro release study were fitted to
various kinetic equations. The kinetic models used were a
zero-order equation, first-order equation, Higuchi’s square
root of time equation and the Korsmeyer–Peppas equation
(Table 3).
Amikacin sulphate release from the polymeric nano-
particles showed a better fit with Korsmeyer–Peppas model
(R2 = 0.999, 0.997, 0.998, 0.998 and 0.997 for formula-
tions AEI, AE2, AE3, AE4 and AE5, respectively) contrary
to the Higuchi model, zero-order model and first-order
model. Fitting the release data up to 60 % of the total
release to the Korsmeyer–Peppas equation proposed that
release of the amikacin sulphate from the polymeric matrix
is through Fickian diffusion (n = 0.44, 0.41, 0.43, 0.44 and
0.41 for formulations AEI, AE2, AE3, AE4 and AE5,
respectively). These results suggest that the amikacin sul-
phate release from the polymeric nanoparticles is through
diffusion.
In vitro antimicrobial activity
Diameter of the zone of inhibition by the marketed eye
drop of amikacin solution was found to be
09.37 ± 0.13 mm at 12 h and 12.24 ± 0.19 mm at 24 h,
Parallelly, diameter of the zone of inhibition for the opti-
mized amikacin sulphate polymeric nanosuspension for-
mulation (AE1) was found to be 10.82 ± 0.11 mm at 12 h
and 13.76 ± 0.17 mm at 24 h. Results predict that devel-
oped nanosuspension possessed prolonged antimicrobial
potency as compared with marketed eye drops (Fig. 5).
In vivo studies
Ocular irritation test
To grow into a realistic and successful advent for any
ophthalmic drug carrier system, ocular tolerance is a
noteworthy characteristic. For the same objective, in vivo
ocular irritation test of amikacin sulphate-loaded polymeric
nanosuspension was determined by Winking test approach.
Results obtained during in vivo study exhibits that irritation
effect produced by optimized formulation is almost same
as of the simulated tear fluid (STF). Since no irritation
effect observed in study, optimized formulation may prove
a realistic and successful advent for any ophthalmic drug
carrier system (Table 4).
In vivo ocular retention study
Increasing the ocular contact time is prime objective for
novel ocular drug delivery systems. For in vivo ocular
retention of amikacin sulphate-loaded polymeric nanopar-
ticles, SEM micrograph of corneal surface and SEM
micrograph of corneal surface later 6 h of treatment with
nanosuspension were taken. Result displays that formu-
lated nanosuspension AE1 of the amikacin sulphate
exhibits corneal adherence for the long time period even
after 6 h of application, which denotes that the optimized
amikacin-loaded nanodispersion was retained for longer
time span giving extended release (Fig. 6a, b).
Permeation study/in vivo release profile
On revealing the data obtained after permeation study it
was observed that on treatment with commercial amikacin
solution, the drug maximum concentration (Cmax) in
aqueous humour was obtained after 1 h whereas on
Fig. 4 % Release of amikacin sulphate from different formulations
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treatment with optimized nanosuspension of amikacin
sulphate (AEI), drug maximum concentration (Cmax) in
aqueous humour was obtained after 2 h. This postpone-
ment in Cmax of amikacin sulphate nanosuspension (AEI)
was owing to the controlled release of the amikacin drug
from the polymeric nanoparticles. Furthermore, drug
maximum concentration (Cmax) produced by nanosuspen-
sion was 1.733 time higher as compared to commercial eye
drop of amikacin. In addition, bioavailability (AUC0-12) of
the nanosuspension was 2.12 time increase in compara-
bility to the commercial eye drop (Fig. 7; Table 5).
Statistical diagnosis verified the appearance of relevant
contrast among the mean (AUC0-12) values for both
treatments at p \ 0.01.
In vivo antibacterial activity
On observing the facts obtained in the end of the test,


















































































































































































































































































































































































































































































































































































Fig. 5 Zone of Inhibition by different amikacin sulphate
formulations
Table 4 Winking counts in 5 min after instillation of 30-ll samples
in rabbit eyes
Groups Formulation Winking count (up to
5 min) n = 3
I Control (STF), pH 7.4 8.00 ± 1.00
II Commercial eye drop
(Amikacin sulphate)
6.98 ± 1.21
III Nanosuspension (AEI) 9.86.0 ± 1.13
Normal winking rate: 1–2/min
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effect when compared with marketed formulation of
amikacin sulphate. Formulation AEI of amikacin sulphate
polymeric nanosuspension provides symptomatic cure
after only 4 days with a dose regimen of two time in a
day, at the same time the commercial amikacin solution
was not able to generate complete symptomatic relief in
6 days with a dose regimen of four times in a day. This
might be owing to excellent bioavailability of amikacin
sulphate from the formulated nanosuspension AEI in
contrast to that of commercial eye drop. Therefore, the
present study proves that the formulated nanosuspension
of amikacin sulphate possesses greater therapeutic out-
comes than that of commercially available amikacin sul-
phate eye drop.
Storage stability studies
outcomes reveals that all batches after even storage
exhibits mean particle sizes below 210 nm, various reports
show that particle size below 210 nm is appropriate for the
ocular application (Amrite et al. 2008). Therefore, opti-
mized formulations in the current study are suitable for an
ocular application. Average particle size of both samples
(AEI and AEI*), rises in a very small amount with respect
to the initial values of both condition refrigerator and at
25 C/60 % RH, it may be due to particle aggregation
during the storage stage. No relevant alterations in drug
content were recorded up to 6 months at both selected
storage environment (Table 6).
Conclusions
Nanosuspensions were prepared by nano emulsification
approach. The principal benefits of the used preparation
techniques are the nullification of toxic organic solvents,
Fig. 6 SEM photomicrograph
(a) control cornea surface
(b) cornea surface after 6 h of
treatment with nanosuspension
Fig. 7 Mean ocular concentration–time profile of amikacin sulphate
Table 5 Pharmacokinetic parameters for amikacin sulphate nano-
suspension (AEI) and commercial amikacin sulphate solution after









11.86 ± 0.7 2 80.37 ± 2.14
Amikacin sulphate solution 06.84 ± 0.4 1 37.82 ± 1.43
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which increases the potential ophthalmic application of the
systems. Polyvinyl alcohol (PVA) was supplemented as a
stabilizing agent to the prepared formulations. Introductory
experimental assessment of formulated polymeric nano-
particles in the solid state like FTIR spectroscopy and TGA
validates that model drug is consistently distributed in the
polymeric vehicle deprived of any interaction or poly-
morph change. Outcomes of FTIR analysis verify that there
is no existence of unusual association forms of drug with
polymers since the peak values are equivalent in both
nanoparticulate systems and drug alone. Findings obtained
from FTIR analysis were additionally confirmed by TGA.
The temperature for the significant weight loss for the drug
was equivalent to the temperature for the significant weight
loss of their corresponding polymeric nanoparticles. The
mean particle size of formulation ranges from 149 to
248 nm with polydispersity index of 0.232–0.468 appro-
priate for ocular administration. In addition, TEM images
showed almost spherical particles with smooth surface. The
positive surface charge on the particle would provide ionic
interaction with the mucous membrane of the cornea,
resulting in sustained drug release and improved ocular
penetration.
Drug release profile of the polymeric nanoparticles
signifies that the drug release was complete with the for-
mulated nanoparticles. Drug release profile also indicates
that drug release from formulation was in controlled
manner and in a common release pattern, i.e. by diffusion
approach. In addition, freeze-dried nanosuspension exhib-
ited good redispersibility upon manual handshaking; the
in vitro release test was reiterated in the polymeric nano
formulation succeeding 6 months of storage at 5 ± 2 and
25 C, 60 % RH; no significant dissimilarities were noticed
in the magnitude of drug release. These conclusions reveal
that formulated polymeric systems possess a consistent
framework that was not modified considerably during
storage. Supplementally, stability investigation conclusions
signify that formulated polymeric nanosuspension has finer
stability and improved self-life as matched to convention-
ally present retailed formulation.
In vivo study manifest that ocular bioavailability of the
polymeric nano formulation was more than that of present
trading eye drops, and polymeric nano formulations are
devoid of any annoyance effect on the cornea for as long as
12 h following administration.
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